Protein-bound polysaccharide Kureha (PSK), one of immunopotentiators, was prescribed for 26 patients with head and neck cancer, from Sept., 1976. Skin sensitivity tests, including DNCB, PPD and PHA, were performed before the administration of PSK, and we found that the patients showed a negative response to more than one antigen.
In addition to irradiation and/or surgery, PSK, 273 g on the average, was administered to the patients for 3 months. Increase in the skin sensitivity of these patients, after 3months, was compared with that of the patients with benign sinus disease who underwent on antrotomy. It was found that increase in skin sensitivity was significantly lower in the cancerous patients with DNCB, but no significant difference was observed with PPD and PHA.
Clinical process in the PSK ingesting patients was variable over 65 years old, and was good under 64 yrs. But they were not significantly related to the change of the skin sensitivity response. Aggravation or metastasis of the primary foci was not seen in 5 out of 8 over 65 years old, and 11 out of 18 under 64 yrs.
抄録全体を表示